Lantern Pharma Inc. (NASDAQ: LTRN) shares have traded higher by 8.26% up to $16.25 in after-market trading. To close Friday at $15.01, Lantern Pharma stock declined -5.06%. Last session, the LTRN stock volume was 0.18 million shares, which was higher than daily volume measured over the last 50 days of the 0.14 million share. The LTRN stock rose in response to news that the number of data points by its platform had increased substantially.
What just happened?
Lantern Pharma is a clinical-stage biopharmaceutical company with a unique AI platform of RADR used to discover biomarkers that predict patient response to its targeted therapeutic pipeline. There are currently four LTRN drug candidates and an advanced cancer treatment program, spanning seven previously undisclosed tumor targets, including two-phase II programs. LTRN’s approach could deliver best-in-class outcomes by targeting drugs at patients whose genomic profile indicate they are most likely to benefit from the drug.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Read More
Lantern Pharma announced last week that RADR had reached 4.6 billion data points. The 16-fold increase in data points over the past 12 months was also accompanied by improving functionality, feature-set, and automation of the drug development platform, as well as RADR covering more drugs, drug classes, and cancer types.
LTRN is committed to growing and enhancing RADR, a drug development platform exclusively for oncology development and rescue, which it believes is among the largest drug development platforms for these therapeutics.
Additional targeting for LTRN’s current pipeline of drug candidates is likely as a result of increasing the number of data points, improving performance, and improving biological relevance of the algorithms.
What’s next?
Now, with the growing data points in the Lantern Pharma (LTRN)’s A.I. platform, collaboration among scientists, biologists, and engineers can take place on issues relating to drug activity, drug response, patient stratification, and cancer biomarkers that had previously been unreachable.
